A meta-analysis on the efficacy and safety of obinuzumab for membranous nephropathy. (PubMed, Sage Open Chronic Dis) - Oct 8, 2026 - "A limited number of observational studies have compared Obinutuzumab's (OBZ) therapeutic potential, with OBZ appearing to be more effective than rituximab (RTX) in achieving clinical remission. High-quality clinical studies are, however, warranted to validate these results further. This study was registered as a meta-analysis in PROSPERO (Number: CRD42025635162)."
Journal • Retrospective data • Glomerulonephritis • Renal Disease
|
|
Qi-Zhang; Chuan-Li Qian; Jing-Rong Qian; Li-Xia Yu; Qi-Feng Liu; Xu-Li Yang
|